Skip to main content
. Author manuscript; available in PMC: 2018 Oct 11.
Published in final edited form as: Cell Rep. 2018 May 29;23(9):2606–2616. doi: 10.1016/j.celrep.2018.04.103

Figure 4. Colony-forming unit (CFU) assay of CD34+ PBSC after treatment with TALEN or CRISPR, AAV6 CD40L cDNA donor and adenoviral helper proteins.

Figure 4.

A) PBSC treated with combinations of TALEN mRNA or CRISPR RNP, AAV6 CD40L cDNA donor and the adenoviral E4orf6/E1b55k helper proteins plated in methylcellulose CFU assay. Numbers of colonies were enumerated after 12–14 days and are represented as percent CFU over total cells plated. Data were analyzed by Wilcoxon Rank-Sum Test. Data are presented as mean ± SD. n=4 experiments, 3 PBSC donors. *p≤0.05, ***p≤0.001, NS = not significant. B) The percentages of the different colony types formed were enumerated. CFU-GEMM (CFU-granulocyte/erythroid/macrophage/megakaryocyte), BFU-E (burst-forming unit-erythroid), CFU-E (CFU-erythroid), CFU-GM (CFU-granulocyte/macrophage), CFU-G (CFU-granulocyte), CFU-GM (CFU-macrophage). C) The percentages of CFU gene-modified at the CD40LG 5’ UTR were determined by ddPCR analysis of genomic DNA from individual CFU.